Saturday September 21, 2019

Blood Test Can Help Diagnose Pre-eclampsia, Says Study

There was no change in the likelihood of complications for the baby, the age at which babies were delivered prematurely or whether they were admitted to a neonatal unit

0
//
Image source- sites.bu.edu

A simple blood test can help diagnose a common but potentially fatal pregnancy complication — pre-eclampsia, finds a study published in The Lancet journal.

During the study, by measuring the concentration of placental growth factor (PlGF) in a woman’s blood, doctors were able to diagnose pre-eclampsia two days sooner on average.

“We knew monitoring PlGF was an accurate way to help detect the condition but were unsure whether making this tool available to clinicians would lead to better care for women. Now we know that it does,” said lead author Lucy Chappell from King’s College London.

Pre-eclampsia, a condition in pregnancy characterised by high blood pressure, sometimes with fluid retention and proteinuria, can cause damage to vital organs, fits and can be fatal for the woman and baby, if left untreated. Globally, 100 women die due to pre-eclampsia every day.

A health service worker takes a blood sample for a malaria test in Dajabon, Dominican Republic, on the border with Haiti, Oct. 6, 2009. A test that doesn't require a needle or blood has won the Africa Prize for Engineering Innovation
A health service worker takes a blood sample for a malaria test in Dajabon, Dominican Republic, on the border with Haiti, Oct. 6, 2009. VOA

“For the last hundred years, we have diagnosed pre-eclampsia by measuring blood pressure and checking for protein in a woman’s urine. These are relatively imprecise and often quite subjective,” Chappell noted.

For the study, the research team studied 1,035 women with suspected pre-eclampsia from 11 maternity units across the UK. They were randomly assigned to two groups — one had their PlGF test results made available to their clinical team, the other did not.

Also Read- AI Method Can Help Treat Brain Tumours: Study

The PlGF testing was shown to reduce the average time to diagnose pre-eclampsia from four to two days and serious complications before birth (such as eclampsia, stroke, and maternal death) to four per cent from five per cent.

There was no change in the likelihood of complications for the baby, the age at which babies were delivered prematurely or whether they were admitted to a neonatal unit, the researchers said. (IANS)

Next Story

Scientists Closing in on Blood Test to Screen People for Possible Signs of Alzheimer’s Disease

A blood test — rather than subjective estimates of thinking skills — could get the right people into studies sooner

0
alzheimer
FILE - Dr. Jori Fleisher, neurologist, examines Thomas Doyle, 66, at the Rush University Medical Center in Chicago, July 9, 2019. VOA

Scientists are closing in on a long-sought goal — a blood test to screen people for possible signs of Alzheimer’s disease and other forms of dementia. On Monday at the Alzheimer’s Association International Conference, half a dozen research groups gave new results on various experimental tests, including one that seems 88% accurate at indicating Alzheimer’s risk.

Doctors are hoping for something to use during routine exams, where most dementia symptoms are evaluated, to gauge who needs more extensive testing. Current tools such as brain scans and spinal fluid tests are too expensive or impractical for regular check-ups.

“We need something quicker and dirtier. It doesn’t have to be perfect” to be useful for screening, said Maria Carrillo, the Alzheimer’s Association’s chief science officer.

Dr. Richard Hodes, director of the National Institute on Aging, called the new results “very promising” and said blood tests soon will be used to choose and monitor people for federally funded studies, though it will take a little longer to establish their value in routine medical care.

alzheimer, hypertension drugs
“Even though no medical treatment is without risk, getting treatment for high blood pressure could be important to maintain brain health in patients with Alzheimer’s disease,” Claassen said. Pixabay 

“In the past year we’ve seen a dramatic acceleration in progress” on these tests, he said. “This has happened at a pace that is far faster than any of us would have expected.”

It can’t come too soon for patients like Tom Doyle, a 66-year-old former university professor from Chicago who has had two spinal fluid tests since developing memory problems four years ago. First he was told he didn’t have Alzheimer’s, then that he did. He ultimately was diagnosed with different problems — Lewy body dementia with Parkinson’s.

“They probably could have diagnosed me years ago accurately if they had had a blood test,” said Doyle, who represents patients on the Alzheimer’s Association’s board.

88% accuracy overall

About 50 million people worldwide have dementia, and Alzheimer’s is the most common form. There is no cure; current medicines just temporarily ease symptoms. Dozens of hoped-for treatments have failed. Doctors think studies may have enrolled people after too much brain damage had occurred and included too many people with problems other than Alzheimer’s.

alzheimer
Poor sleep can predict Alzheimer’s Risk in elderly. Pixabay

A blood test — rather than subjective estimates of thinking skills — could get the right people into studies sooner. One of the experimental blood tests measures abnormal versions of the protein that forms the plaques in the brain that are the hallmark of Alzheimer’s. Last year, Japanese researchers published a study of it and on Monday they gave results from validation testing on 201 people with Alzheimer’s, other types of dementia, mild impairment or no symptoms.

The blood test results closely matched those from the top tests used now — three types of brain scans and a mental assessment exam, said Dr. Akinori Nakamura of the National Center for Geriatrics and Gerontology in Obu, Japan. The test correctly identified 92% of people who had Alzheimer’s and correctly ruled out 85% who did not have it, for an overall accuracy of 88%. Shimadzu Corp. has rights to the test and is working to commercialize it, Nakamura said.

Ruling out disorders

Another experimental test looks at neurofilament light, a protein that’s a marker of nerve damage. Abdul Hye of King’s College London gave results of a study comparing blood levels of it in 2,300 people with various neurological conditions — Alzheimer’s, other dementias, Parkinson’s, depression, multiple sclerosis, Lou Gehrig’s disease — plus healthy folks for comparison.

Levels were significantly higher in eight conditions, and only 2% of healthy folks were above a threshold they set for raising concern. The test doesn’t reveal which disorder someone has, but it may help rule one out when symptoms may be psychological or due to other problems.

alzheimer
Like the Japanese test, it measures the abnormal Alzheimer protein, and the new results will show how well the test reflects what brain scans show on nearly 500 people. Pixabay

Later at the conference, Dr. Randall Bateman of Washington University School of Medicine in St. Louis will give new results on a blood test he helped develop that the university has patented and licensed to C2N Diagnostics, a company he co-founded. Like the Japanese test, it measures the abnormal Alzheimer protein, and the new results will show how well the test reflects what brain scans show on nearly 500 people.

“Everyone’s finding the same thing … the results are remarkably similar across countries, across techniques,” said Bateman, whose work is supported by the U.S. government and the Alzheimer’s Association. He estimates a screening test could be as close as three years away.

ALSO READ: Healthy Lifestyle Can Cut Risk of Developing Alzheimer Even if You Have High Genetic Risk: Study

What good will that do without a cure?

An Associated Press-NORC Center for Public Affairs Research poll last year found that most Americans would want to know if they carried a gene tied to a disease even if it was incurable. “What people want most of all is a diagnosis” if they’re having symptoms, said Jonathan Schott of University College London. “What we don’t like is not knowing what’s going on.” (VOA)